Bosentan monohydrate

This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2-bipyrimidin)-4-yl)benzenesulfornamide but more generally known as bosentan, which bears US NIH Compound Identifier 104865. Bosentan most often comes in basic and hydrate forms. European Medicines Agency schedules Bosentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05877MIG. World Health Organization schedules bosentan in its Anatomical Therapeutic Chemical (ATC) Classification. BOSENTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bosentan monohydrate under HS 29350090 and SITC 51580. SMILES: CC(C)(C)C1CCC(CC1)S(=O)(=O)NC2C(C(NC(N2)C3NCCCN3)OCCO)OC4CCCCC4OC.O.